

Presentations

- (1) **Ng HS**, Tremlett H. Disease-Modifying Drug Safety and Effectiveness in Multiple Sclerosis (DRUMS). Virtual poster presentation at *MS Connect Conference*, Virtual conference, November 2020. Main audience: general public.
- (2) **Ng HS**, Zhu F, Kingwell E, Zhao Y, Yao S, Ekuma O, Svenson LW, Evans C, Fisk JD, Marrie RA, Tremlett H. Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Virtual poster presentation at *European Charcot Foundation's 28th Annual meeting*, Virtual meeting, November 2020.
- (3) **Ng HS**, Zhu F, Kingwell E, Zhao Y, Evans C, Svenson L, Fisk JD, Marrie RA, Tremlett H. Characteristics of a population exposed to a disease-modifying drug for multiple sclerosis in the real-world setting (1996-2017). Virtual oral and poster presentations at *Canadian Association of Population Therapeutics (CAPT-ACTP) 2020 Conference*, Virtual conference, October 2020.
- (4) **Ng HS**, Zhu F, Kingwell E, Zhao Y, Evans C, Svenson L, Fisk JD, Marrie RA, Tremlett H. Characteristics of a population exposed to a disease-modifying drug for multiple sclerosis in the real-world setting (1996-2017). Virtual poster presentation at *8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting [MSVirtual2020]*, Virtual meeting, September 2020.
- (5) **Ng HS**, Kingwell E, Zhu F, Zhang T, Marrie RA, Carruthers R, Tremlett H. Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: a population-based study. Virtual poster presentation at *36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management [ICPE All Access 2020]*, Virtual conference, September 2020.
- (6) **Ng HS**, Luzon C, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Virtual poster presentation at *36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management [ICPE All Access 2020]*, Virtual conference, September 2020.
- (7) **Ng HS**. Disease-Modifying Drug Safety and Effectiveness in Multiple Sclerosis (DRUMS). Virtual oral presentation (a 5-minute presentation and a 2-minute elevator pitch) to expert panels as part of the *Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Program*, Webinar, March 2020.
- (8) **Ng HS**, Kingwell E, Zhu F, Zhang T, Marrie RA, Carruthers R, Tremlett H. Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: a population-based study. Poster presentation at *5th ACTRIMS Forum 2020*, West Palm Beach, United States, February 2020.
- (9) **Ng HS**, Luzon C, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Poster presentation at *5th ACTRIMS Forum 2020*, West Palm Beach, United States, February 2020.
- (10) Chertcoff A, **Ng HS**, Zhu F, Zhao Y, Kingwell E, Tremlett H. Alemtuzumab and prescription medication use in the MS population. Poster presentation at *5th ACTRIMS Forum 2020*, West Palm Beach, United States, February 2020.

- (11) **Ng HS**, Tremlett H. Disease-Modifying Drug Safety and Effectiveness in Multiple Sclerosis (DRUMS). Poster presentation at *ACTRIMS Young Scientist Summit on Clinical Neuroimmunology*, Austin, United States, January 2020.
- (12) **Ng HS**, Luzon C, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Poster presentation at *Multiple Sclerosis Society of Canada's endMS Conference 2019*, Calgary, Canada, December 2019.
- (13) **Ng HS**, Tremlett H. Disease-Modifying Drug Safety and Effectiveness in Multiple Sclerosis (DRUMS). Poster presentation at *British Columbia and Yukon (BCY) MS Connect'19 Conference*, Vancouver, Canada, October 2019. Main audience: general public.
- (14) **Ng HS**, Luzon C, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Poster presentation at *35th Congress of the ECTRIMS and 24th Annual Conference of Rehabilitation in MS*, Stockholm, Sweden, September 2019.
- (15) **Ng HS**, Tremlett H. Disease-Modifying Drug Safety and Effectiveness in Multiple Sclerosis (DRUMS). Poster presentation at *2019 DSECT Program Annual Symposium*, Toronto, Canada, April 2019.
- (16) **Ng HS**. Disease-Modifying Drug Safety and Effectiveness in Multiple Sclerosis (DRUMS). Oral presentation at *Patient and Stakeholder Engagement in Research Workshop*, University of British Columbia, Vancouver, Canada, March 2019.
- (17) **Ng HS**, Koczwara B, Roder D, Chan RJ, Vitry A. Patterns of health service utilisation among the Australian population with cancer compared to the general population. Poster presentation at *Clinical Oncology Society of Australia (COSA)'s 45th Annual Scientific Meeting*, Perth, Australia, November 2018.
- (18) **Ng HS**, Vitry A, Koczwara B, Roder D, McBride ML. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Oral presentation at *COSA's 45th Annual Scientific Meeting*, Perth, Australia, November 2018.
- (19) **Ng HS**. Assessment of comorbidities in the population with cancer using Big Data. Oral presentation at *University of British Columbia's Centre for Health Services and Policy Research (CHSPR) Seminar*, Vancouver, Canada, June 2018.
- (20) **Ng HS**. Assessment of comorbidities in the population with cancer using Big Data. Oral presentation at *BC Cancer, Cancer Control Research Seminar*, Vancouver, Canada, June 2018.
- (21) **Ng HS**, Koczwara B, Roder D, Vitry A. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Oral presentation at *Australasian Pharmaceutical Science Association and Australasian Society of Clinical and Experimental Pharmacologists and Toxicologist (APSA-ASCEPT) Joint Scientific Meeting*, Brisbane, Australia, December 2017.
- (22) **Ng HS**, Koczwara B, Roder D, Niyonsenga T, Vitry A. Incidence of comorbidities in women with breast cancer treated with tamoxifen or an aromatase inhibitor: an Australian population-based cohort study. Oral presentation at *International Society for Pharmacoepidemiology (ISPE)'s 10th Asian Conference on Pharmacoepidemiology (ACPE 2017)*, Brisbane, Australia, October 2017.
- (23) **Ng HS**, Koczwara B, Roder D, Vitry A. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-

based cohort study. Oral presentation at *South Australia (SA) State Population Health Conference*, Adelaide, Australia, October 2017.

- (24) **Ng HS**. Assessment of the burden, types and development of comorbidities in the Australian population with cancer. Invited oral presentation at *Sungkyunkwan University's School of Pharmacy Graduate Research Student Seminar*, Seoul, Republic of South Korea, February 2017.
- (25) **Ng HS**, Koczwara B, Roder D, Niyonsenga T, Vitry A. Development of comorbidities in women with hormone-dependent breast cancer: an Australian population-based analysis. Poster presentation at *Cancer Survivorship Conference*, Adelaide, Australia, February 2017.
- (26) **Ng HS**, Roder D, Vitry A. Prevalence of comorbidities and health status among current cancer and cancer survivors: an Australian population-based study. Poster presentation at the *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 7th Asia-Pacific Conference*, Singapore, Singapore, September 2016.
- (27) **Ng HS**. Assessment of the burden, types and development of comorbidities in the Australian population with cancer. Oral presentation at *National Cardiotoxicity Position Statement Meeting*, Adelaide, Australia, July 2016.
- (28) **Ng HS**, Roder D, Vitry A. Prevalence of comorbidities among current cancer and cancer survivors: an Australian-population based study. Oral presentation at *UniSA School of Pharmacy and Medical Sciences Bi-Annual Symposium*, Adelaide, Australia, June 2016.